Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)

NCT01419691 ↗

Phase 2 Completed 15 enrolled University of Kansas Medical Center Kansas Bioscience Authority · collab The Leukemia and Lymphoma Society · collab Therapeutics for Rare and Neglected Diseases (TRND) · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and effectiveness of auranofin to treat patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic lymphoma (PLL).

Timeline

Start: 2011-09
Primary completion: 2015-09
Completion: 2015-09

Publications

Rousselle B, Massot A, Privat M, Dondaine L, Trommenschlager A, Bouyer F, Bayardon J, Ghiringhelli F, Bettaieb A, Goze C, Paul C, Malacea-Kabbara R, Bodio E. Conception and Evaluation of Fluorescent Phosphine-Gold Complexes: From Synthesis to in vivo Investigations. ChemMedChem. 2022 Jun 3;17(11):e202100773. doi: 10.1002/cmdc.202100773. Epub 2022 Mar 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Auranofin	Small molecule	6 mg	Oral

Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)

Summary

Timeline

Publications

Drugs

Indications